Ibex Wealth Advisors purchased a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 6,918 shares of the exchange traded fund’s stock, valued at approximately $884,000.
Several other hedge funds have also added to or reduced their stakes in the stock. Financial Life Planners purchased a new stake in shares of SPDR S&P Biotech ETF during the 1st quarter worth approximately $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $27,000. Intesa Sanpaolo Wealth Management bought a new position in SPDR S&P Biotech ETF during the fourth quarter valued at $30,000. SHP Wealth Management bought a new position in SPDR S&P Biotech ETF during the fourth quarter valued at $31,000. Finally, Legacy Wealth Managment LLC ID purchased a new stake in SPDR S&P Biotech ETF in the fourth quarter worth $32,000.
SPDR S&P Biotech ETF Price Performance
Shares of XBI opened at $164.28 on Friday. The firm has a market cap of $11.19 billion, a PE ratio of 11.47 and a beta of 0.82. The stock’s fifty day moving average price is $139.81 and its two-hundred day moving average price is $131.18. SPDR S&P Biotech ETF has a 1 year low of $84.39 and a 1 year high of $165.71.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
